Quotes 5-day view Delayed Nasdaq
11/19/2020
11/20/2020
11/23/2020
11/24/2020
11/25/2020
Date
112.82(c)
114.37(c)
114.69(c)
118.88(c)
123.78 Last
305 356
266 546
192 685
398 173
46 389 Volume
-1.08% +1.37% +0.28% +3.65% +4.12% Change
Sales 2020
247 M - -
Net income 2020
-240 M - -
Net cash position 2020
663 M - -
P/E ratio 2020
-30,7x
Yield 2020
-
Sales 2021
330 M - -
Net income 2021
-277 M - -
Net cash position 2021
445 M - -
P/E ratio 2021
-28,0x
Yield 2021
-
Capitalization
7 865 M 7 865 M -
EV / Sales 2020
29,1x
EV / Sales 2021
22,5x
Nbr of Employees
740
Free-Float
94,6%
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies....
Notations Surperformance© of Ultragenyx Pharmaceutical Inc.
Trading Rating : Investor Rating :
All news about ULTRAGENYX PHARMACEUTICAL INC.
News in other languages on ULTRAGENYX PHARMACEUTICAL INC.
- No features available -
ULTRAGENYX PHARMACEUTICAL INC. - 10/30
The underlying trend is in force again
BUY
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
15
Average target price
105,65 $
Last Close Price
118,88 $
Spread / Highest target
7,67%
Spread / Average Target
-11,1%
Spread / Lowest Target
-46,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
